Candel Therapeutics, Inc. (CADL) Stock Analysis

Free AI-powered analysis and research for Candel Therapeutics, Inc. stock

Sector: Healthcare

Analyze Candel Therapeutics, Inc. (CADL) Stock

Candel Therapeutics, Inc. (CADL) is a leading company in the Healthcare sector. Use StockIQ's free analysis tool to get comprehensive insights into CADL stock performance, technical indicators, and AI-powered trading recommendations.

Get instant AI-powered analysis including technical indicators, fundamental analysis, risk assessment, and trading insights for Candel Therapeutics, Inc. stock.

Analyze CADL Now →

📰 Latest Update

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Tue, June 2, 2026 at 12:05 PM UTC 2 min read

Candel Therapeutics announced the publication of pivotal Phase 3 data in The Lancet Oncology, showcasing significant improvements in disease-free survival for its treatment Aglatimagene Besadenovec (CAN-2409) in localized prostate cancer. This positive data highlights the potential of CAN-2409 as a promising therapeutic option, which could enhance the company's market position and attract investor interest. The results may also pave the way for future regulatory approvals and increased revenue opportunities.

Read full article →